MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by macrophages and is a promising therapeutic strategy

Christian M Schürch, Matthias A Roelli, Stefan Forster, Marie-Hélène Wasmer, Frido Brühl, Renaud Maire, Sergio Di Pancrazio, Marc-David Ruepp, Roland Giger, Aurel Perren, Anja Schmitt, Philippe Krebs, Roch-Philippe Charles, Matthias S Dettmer
Thyroid: Official Journal of the American Thyroid Association 2019 April 2
30938231

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers with a median survival of only 3-6 months. Standard treatment options and even targeted therapies have so far failed to improve long-term overall survival. Thus, novel treatment modalities for ATC, such as immunotherapy, are urgently needed. CD47 is a "don't eat me" signal which prevents cancer cells from phagocytosis by binding to signal regulatory protein α (SIRPα) on macrophages. So far, the role of macrophages and the CD47-SIRPα signaling axis in ATC is not well understood.

METHODS: We analyzed 19 primary human ATCs for macrophage markers, CD47 expression and immune checkpoints by immunohistochemistry. ATC cell lines and a fresh ATC sample were assessed by flow cytometry for CD47 expression and macrophage infiltration, respectively. CD47 was blocked in phagocytosis assays of co-cultured macrophages and ATC cell lines. Anti-CD47 antibody treatment was administered to ATC cell line xenotransplanted immunocompromised mice as well as to tamoxifen-induced ATC double-transgenic mice.

RESULTS: Human ATC samples were heavily infiltrated by CD68- and CD163-expressing tumor-associated macrophages (TAMs), and expressed CD47 and calreticulin, the dominant pro-phagocytic molecule. In addition, ATC tissues expressed the immune checkpoint molecules programmed cell death 1 (PD-1) and PD-1 ligand 1 (PD-L1). Blocking CD47 promoted the phagocytosis of ATC cell lines by macrophages in vitro. Anti-CD47 antibody treatment of ATC xenotransplanted mice increased the frequency of TAMs, enhanced the expression of macrophage activation markers, augmented tumor cell phagocytosis, and suppressed tumor growth. In double-transgenic ATC mice, CD47 was expressed on tumor cells and blocking CD47 increased TAM frequencies.

CONCLUSIONS: Targeting CD47 or CD47 in combination with PD-1 may potentially improve the outcomes of ATC patients and may represent a valuable addition to the current standard of care.

Comments

You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Trending on Read

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
30938231
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"